Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension.

Background: This was a phase 3, randomized, double-blind, placebo-controlled study.

Methods: Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo ( = 65), azilsartan medoxomil (AZL-M) 40 mg ( = 132), or AZL-M 80 mg ( = 131). The primary endpoint was the change from baseline to week 6 in trough scSBP.